9 completed, 4 terminated, 2 recruiting, 1 active not recruiting. 13 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 8, Terminated 3, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 7 | Terminated 3, Recruiting 2, Active not recruiting 1, Completed 1 |
Follow Interleukin-15: new trials by email Literature Review of Interleukin-15 trials Research Report on Interleukin-15
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors EBNK-001 + IL-15 + Pembrolizumab - Cancer, Sarcoma | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 83 | 2026-02-01 | 2026-02-18 |
| PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC PD-L1 t-haNK, Cetuximab, NAI - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 25 | 2024-02-16 | 2026-10-19 |
| "Phase I / II Study on Infusion of Natural Killer Cells After Haploidentical Transplantation in Pediatric Patients" NK cells stimulated ex vivo with IL-15, Alloreactive NK cells - High-risk Leukemias | Phase 1 / Phase 2 | Active not recruiting | Instituto de Investigación Hospital Universitario La Paz | 18 | 2020-11-30 | 2025-04-06 |
| Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma rhIL-15, Avelumab - Clear-Cell Renal Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2020-05-26 | 2022-05-17 |
| Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome Recombinant human Interleukin-15 (rhIL-15), Mogamulizumab - Adult T-Cell Lymphoma/Leukemia, Sezary Syndrome | Phase 1 | Completed | National Cancer Institute (NCI) | 6 | 2020-02-26 | 2023-01-04 |
| Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia rhIL-15, Obinutuzumab - Leukemia, Lymphocytic | Phase 1 | Terminated | National Cancer Institute (NCI) | 1 | 2019-07-11 | 2022-03-22 |
| Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies rhIL-15, Avelumab - Peripheral T-cell Lymphoma NOS, Mycosis Fungoides | Phase 1 | Completed | National Cancer Institute (NCI) | 8 | 2019-06-07 | 2022-09-13 |
| QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer ETBX-011, ALT-803 - Thyroid Cancer, Colon Cancer | Phase 1 / Phase 2 | Terminated | NantCell, Inc. | 3 | 2017-06-26 | 2024-08-06 |
| Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) IL-15 plus, alemtuzumab - T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL) | Phase 1 | Completed | National Cancer Institute (NCI) | 11 | 2017-01-19 | 2022-04-29 |
| MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients IL-15 - Acute Myelogenous Leukemia | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 17 | 2015-10-01 | 2018-02-20 |
| NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors Recombinant human interleukin-15 (rhIL-15), NK Cell Infusion - Solid Tumors, Brain Tumors | Phase 1 | Completed | National Cancer Institute (NCI) | 16 | 2013-06-11 | 2026-09-01 |
| Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Human Interleukin-15 - Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 20 | 2013-02-15 | 2017-09-15 |
| Continuous Infusion of rhIL-15 for Adults With Advanced Cancer rh IL-15 (10 DAYS), rh IL-15 (5 DAYS) - Lymphoma, Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 38 | 2012-04-04 | 2023-03-06 |
| Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) Preparative Regimen, Intravenous Recombinant Human IL-15 (rhIL-15) - Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 1 | Completed | Masonic Cancer Center, University of Minnesota | 26 | 2011-09-01 | 2025-07-24 |
| Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes - Metastatic Melanoma, Skin Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 3 | 2011-05-01 | 2015-01-27 |
| Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults PennVax B, IL-12, IL-15 - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 120 | 2007-10-01 | 2021-10-14 |
Melanoma (3) · Breast Neoplasms (2) · Carcinoma, Renal Cell (2) · Leukemia (2) · Leukemia, Myeloid, Acute (2) · Lung Neoplasms (2) · Lymphoma, T-Cell, Cutaneous (2) · Mycosis Fungoides (2) · Neoplasm Metastasis (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Sarcoma (2) · Sezary Syndrome (2) · Squamous Cell Carcinoma of Head and Neck (2) · Brain Neoplasms (1)
National Cancer Institute (NCI) (9) · Masonic Cancer Center, University of Minnesota (2) · Dana-Farber Cancer Institute (1) · Essen Biotech (1) · Instituto de Investigación Hospital Universitario La Paz (1) · NantCell, Inc. (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (14) · China (1) · Spain (1)
Kevin C Conlon, M.D. (4) · Jeffrey Miller (1) · Jeffrey Miller, MD (1) · Jeffrey S Miller, MD (1) · Kevin Conlon, M.D. (1) · Michael Dennis, MD (1) · Milos Miljkovic, M.D. (1) · Rosandra N Kaplan, M.D. (1) · Scott Parker, MD (1) · Steven A Rosenberg, M.D. (1)
PMID 33883258, PMID 32508818, PMID 31266741, PMID 25820067, PMID 29203590, PMID 30045932, PMID 31142503, PMID 35475910, PMID 40546724
2019 (1), U01CA154967 (1)